seed
Stage
About
Vasa Therapeutics is a biopharmaceutical company developing therapeutics that target the pathophysiology of cardiovascular aging. Its pipeline includes VS-041, a narrow‑spectrum MMP‑2/9 inhibitor in development for heart failure with preserved ejection fraction (HFpEF), and apelin analog programs targeting peripheral artery disease, neuromuscular disorders and sarcopenia.
Explore Vasa Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.